Fosnetupitant
As of the edition of 20 October 2026, Fosnetupitant is a small molecule: marketed, first approved in 2018 (US); acts on TACR1; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Akynzeo
- First approved
- 19 April 2018 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Taiho; 2 holders in all
- Registered trials
- 3, 1 stopped early
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by Helsinn Healthcare.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product10 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 10 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR1 | Substance-P receptor | P25103 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taiho | Applicant | 2022 to now |